ClinicalTrials.gg
CompletedNCT04037618Updated Sep 11, 2019

Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]-EYP001a After a Single Oral Dose

A Phase 1 interventional study of [14C]-EYP001a in Healthy, sponsored by Enyo Pharma. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-11.

Sponsored by Enyo Pharma · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
Male
01

Study summary

The study is designed to investigate the absorption, metabolism, and excretion of EYP001a as well as the safety/tolerability of EYP001a following the administration of a single oral dose to healthy male volunteers. The EYP001a dose is administered in a [14C]-labeled form to enable detection and quantitation of dose-related material independent of possible biotransformation.

Read the detailed description

This is a single site, open-label, mass balance phase 1 study.

Six healthy male subjects will receive a single oral dose A of [14C]-EYP001a containing 100 μCi radioactivity.

  • Eligibility is assessed during a screening period of up to 4 weeks.
  • Subjects will check into the clinic one day prior to dosing (Day -1) for baseline assessments and to (re-)confirm eligibility.
  • The study drug will be administered on Day 1, after an overnight fast of at least 10 hours.
  • Blood, urine and fecal samples will be collected up to and including Day 4. If the study discharge criteria are not met on Day 4, blood, urine and fecal samples will be collected in 24- hour intervals until the study discharge criteria are met.
  • An End of Study Visit will be planned at Day 14 (+/- 1 Day).
02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Enyo Pharma is the lead sponsor of 12 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to provide to participate in this study.
  • Healthy and free from illness or disease as determined by medical history, physical examination, laboratory and other tests at Screening.
  • A body weight of ≥60 kg and a ranging from 18.0 to 35.0 kg/m2 at Screening.
  • Subject must agree to minimize the risk of a female partner becoming pregnant from the dosing day until 3 months after the completion of the study. Acceptable methods of for male volunteers include abstinence from sexual intercourse, a vasectomy no less than 6 months prior to dosing, barrier contraception or a medically accepted contraceptive method. For female partners of male volunteers, acceptable methods of contraception include intra-uterine device (which should be placed at least 1 month before the start of the study), tubal ligation (which took place at least 6 months prior to the start of the study), hormonal contraceptive since at least two months and diaphragm with spermicide. If the subject is a sperm donor, the subject must agree not to donate sperm during the study and until 90 days after the last intake of study drug.
  • In the Investigator's opinion, subject is able to understand the nature of the study and any risks involved in participation, and willing to cooperate and comply with the protocol restrictions and requirements.

Exclusion criteria

Exclusion Criteria:

  • Any finding of the medical examination (including blood pressure, pulse rate and ) deviating from normal and of clinical relevance.
  • History or current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hormonal disorders.
  • History of any major surgery within the last 4 weeks before participation in this study or any bone fracture within the last 2 months.
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders.
  • Chronic or relevant acute infections.
  • History of allergy/ (including drug allergy) which is deemed relevant to the trial as judged by the investigator.
  • History of any bleeding disorder including prolonged or habitual bleeding, other hematologic disease or cerebral bleeding (e.g. after a car accident) or commotion cerebri.
  • Intake of drugs with a long half-life (>24 hours) within 1 month prior to study drug administration.
  • Use of any kind of prescription medication from 14 days prior to the administration of the study drug.
  • Use of any kind of over-the-counter products and/or natural health products (including food supplements, herbal supplements, etc.) from 7 days prior to the administration of the study drug.
  • Participation in another trial with an drug within 2 months prior to administration of the study drug or during the trial.
  • The subject is a smoker or uses other nicotine-containing products.
  • Alcohol abuse.
  • History of drug abuse.
  • Blood donation within 3 months prior to administration or during the trial.
  • Any laboratory value outside the reference range, unless considered to lack clinical relevance.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    [14C]-EYP001a

    \[14C\]-EYP001a dose A containing 100 μCi radioactivity

    Drug: [14C]-EYP001a

Interventions

  • Drug[14C]-EYP001a

    Oral drinking suspension

06

What researchers measure

Primary outcomes

  1. Radioactivity-time profiles in whole blood and plasma

    Time frame: Day 1 to Day 4 or until discharge

  2. Cmax

    Maximum observed total radioactivity in plasma and whole blood

    Time frame: Day 1 to Day 4 or until discharge

  3. tmax

    Time from dosing to peak total radioactivity in plasma and whole blood

    Time frame: Day 1 to Day 4 or until discharge

  4. AUC0-24

    Area under the total radioactivity-time curve in plasma and whole blood from time zero to 24 hours

    Time frame: 0 to 24 hours

  5. [14C]-metabolic profile and identification of metabolites in plasma

    Time frame: Day 1 to Day 4 or until discharge

  6. [14C]-radioactivity in urine

    Time frame: Day 1 to Day 4 or until discharge

  7. [14C]-metabolic profile and identification of metabolites in urine

    Time frame: Day 1 to Day 4 or until discharge

  8. [14C]-radioactivity in feces

    Time frame: Day 1 to Day 4 or until discharge

  9. [14C]-metabolic profile and identification of metabolites in feces

    Time frame: Day 1 to Day 4 or until discharge

Secondary outcomes

  1. Number of subjects with adverse events

    Time frame: Day 1 to Day 4 or until discharge

07

Study locations

1 site
  • QPS Netherlands B.V.
    Groningen, 9713, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Jul 2019, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2019
First posted
Jul 30, 2019
StartActual
Jul 24, 2019
Primary completionActual
Jul 27, 2019
CompletionActual
Aug 6, 2019
Last update
Sep 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04037618
Lead sponsor
Enyo Pharma
Responsible party
Sponsor
First posted
Jul 30, 2019
Start date
Jul 24, 2019
Primary completion
Jul 27, 2019
Completion
Aug 6, 2019
Last update
Sep 11, 2019

Study contacts

C. Voors-Pette, MD
principal investigator · QPS Netherlands B.V.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion